S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries (2014/12/23)|
|ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries (2014/12/30)|
|ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years (2015/1/13)|
|ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer (2015/1/22)|
|ARIAD Reports 2014 Financial Results, Provides 2015 Financial Guidance and Outlines Strategic Objectives (2015/2/19)|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial (2014/12/8)|
|ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia (2014/12/9)|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial (2014/12/9)|
|ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015 (2015/1/6)|
|ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe (2015/1/20)|
Click above to view more mutual fund data and stats for aria - ARIAD Pharmaceuticals Inc.